First, a broad understanding of the cellular events such as autophagy levels, ROS levels, and VPS4A and VPS4B levels can enable the strict screening of NSCLC patient populations suitable for ALO treatment. This evidence concerns the gene VPS4B and non-small cell lung carcinoma.